Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (241-250 of 304) with videos related to

Pageof 31
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2018
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaA K Krug, D Enderle, C Karlovich, et al.
Environmental Research Letters : ERL [Web Site]|March 27, 2026
Benzene and other hazardous air pollutants in consumer-grade natural gas in EuropeTamara L Sparks, Yannai S Kashtan, Sebastian T Rowland, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2020
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III studyJonathan W Goldman, Marina Chiara Garassino, Yuanbin Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaA K Krug, D Enderle, C Karlovich, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
ESMO Open|March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANL Paz-Ares, Y Chen, N Reinmuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA TrialThomas John, Christian Grohé, Jonathan W Goldman, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Pageof 31

Showing results (241-250 of 304) with videos related to

Sort By:
Pageof 31
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2018
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaA K Krug, D Enderle, C Karlovich, et al.
Environmental Research Letters : ERL [Web Site]|March 27, 2026
Benzene and other hazardous air pollutants in consumer-grade natural gas in EuropeTamara L Sparks, Yannai S Kashtan, Sebastian T Rowland, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2020
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III studyJonathan W Goldman, Marina Chiara Garassino, Yuanbin Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaA K Krug, D Enderle, C Karlovich, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
ESMO Open|March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANL Paz-Ares, Y Chen, N Reinmuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA TrialThomas John, Christian Grohé, Jonathan W Goldman, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Pageof 31